Healthcare

Trump’s drug-price crackdown misses the mark, experts say

By Robert King
Published March 13, 2018 5:01am ET
Add Washington Examiner on Google
Trump’s drug-price crackdown misses the mark, experts say
In this photo from Feb. 24, Department of Health and Human Services Secretary Alex Azar speaks in Washington, D.C. So far, Azar and the Trump administration want to leverage greater competition in the pharmaceutical market to entice lower prices. (AP Photo/Jose Luis Magana) | Jose Luis Magana

Less than a month into his new job, Alex Azar got some praise from his new boss, President Trump.

The newly minted head of the Department of Health and Human Services had already done a great job lowering drug prices, according to Trump.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Alex Azar Department of Health and Human Services Donald Trump FDA Henry Waxman Insurance Industry Medicare and Medicaid Patent Law Pharmaceutical Industry Robert King Ron Wyden Senate